Abstract: Method for producing an extract or extract formulation of the fruit of Canarium odontophyllum comprising or consisting of the following steps: (i) providing fruit material from Canarium odontophyllum, wherein said fruit material essentially consists of the endocarp of the seeds of Canarium odontophyllum, (i-a) optionally drying the fruit material provided in step (i), (ii) extracting the fruit material provided in step (i) or (i-a) with a mixture essentially consisting or consisting of water and an alcohol having 1 to 3 carbon atoms or consisting water and acetonitrile, (iii) optionally partially or fully removing the alcohol having 1 to 3 carbon atoms of step (ii), and optionally adding an organic solvent of medium polarity to said aqueous residue and extracting the aqueous residue with said organic solvent or a supercritical solvent, such as supercritical carbon dioxide thereby obtaining an enriched extract, (iv) optionally mixing the extract obtained in step (ii) or the enriched extract obtained in

Abstract: The use or methods of use of extracts comprising one or more special clerodane compounds against inflammatory (including allergic) diseases or conditions, as well as novel compounds of this type, said clerodane derivatives for use against inflammatory (including allergic) diseases or conditions, pharmaceutical formulations comprising them especially for use against inflammatory disease or conditions, and related embodiments; said extract and/or compound(s) for use in the treatment or in the preparation of a medicament (including a nutraceutical) for the prophylactic and/or therapeutic treatment of said disease or condition, as well as their preparation; pharmaceutical or nutraceutical formulations comprising said extract and/or natural compound(s) which are useful in said prophylactic and/or therapeutic treatment, and related embodiments.

Abstract: The present invention primarily relates to the use of certain extract formulations of Rhodamnia cinerea as defined herein as alpha-amylase inhibitors and as actives for the therapeutic (including prophylactic) treatment of a carbohydrate metabolic disorder or of a disease attendant on hyperglycemia, preferably selected from the group consisting of prediabetes, obesity, hyperlipemia, arteriosclerosis, arteriolosclerosis, atherosclerosis, diabetes, postprandial hyperglycemia, and metabolic syndrome. The present invention also relates to corresponding methods. The invention further relates to specific extract formulations obtainable from Rhodamnia cinerea and to compositions, in particular orally consumable compositions, comprising an effective amount of such an extract formulation.

Abstract: The use or methods of use of extracts comprising one or more special clerodane compounds against inflammatory (including allergic) diseases or conditions, as well as novel compounds of this type, said clerodane derivatives for use against inflammatory (including allergic) diseases or conditions, pharmaceutical formulations comprising them especially for use against inflammatory disease or conditions, and related embodiments; said extract and/or compound(s) for use in the treatment or in the preparation of a medicament (including a nutraceutical) for the prophylactic and/or therapeutic treatment of said disease or condition, as well as their preparation; pharmaceutical or nutraceutical formulations comprising said extract and/or natural compound(s) which are useful in said prophylactic and/or therapeutic treatment, and related embodiments.

Abstract: The invention relates to cyclopentabenzofuran derivatives for the treatment and/or prophylaxis of angiogenesis-related disorders.

Abstract: The present invention relates to the use of compounds of isopimarane diterpene type, e.g. obtainable as or from extracts from Orthosiphon species, especially certain enriched or purified specific compounds therefrom, as well as said compounds or extracts for use or methods of using said compounds or extracts in the management of cognitive performance; in mammals, especially humans, respectively. The isopimarane diterpene type compounds can be of the formula wherein the symbols are as defined in the description and claims.

Abstract: The invention relates to aurones and extracts comprising them useful in the prophylactic and/or therapeutic treatment of an animal (including a human) with a phosphodiesterase (PDE) dependent disease or condition of the central nervous system, as well as methods, uses and other inventions related thereto.

Abstract: The invention relates to aurones and extracts comprising them useful in the prophylactic and/or therapeutic treatment of an animal (including a human) with an estrogen receptor (ER) related disease or condition of the animal or human body, as well as methods, uses and other inventions related thereto.

Abstract: The invention relates to the use of cycloventabenzofuran derivatives for the production of a medicament for the treatment of nuclear factor of &kgr;B-dependent diseases.

Abstract: A process for removing finishing agents containing silicone oil from textile substrates in an aqueous medium free of halogenated hydrocarbons, wherein the removing agent is a composition containing, as an essential ingredient, a surfactant carrying cationic groups on the surfactant framework structure, and which may also contain acids, non-ionic surfactants, water-soluble non-ionic polymers and solvents (free of halogenated hydrocarbons).

Abstract: The present invention relates to a method for textile printing with aqueous dispersions in which an organic fixing agent is crosslinked with a blocked polyisocyanate having (i) an average molecular weight of about 800 to about 25,000, (ii) a content of blocked isocyanate groups, calculated as free NCO and based on non-blocked polyisocyanate, corresponding to an NCO content of about 5 to about 20% by weight, (iii) an ionic group content of about 1 to about 75 milliequivalents per 100 g of blocked polyisocyanate, and (iv) a content of polyalkylene oxide units of about 1 to about 20% by weight, based on blocked polyisocyanate, said blocked polyisocyanate being obtained by the reaction of(a) organic polyisocyanates,(b) isocyanate-reactive compounds containing (potential) ionic groups,(c) polyalkylene ether alcohols,(d) NCO blocking agents, and(e) optionally, isocyanate-reactive compounds that are different from components (b), (c), and (d).